ArticleCureus2023
Novel Corona Virus 2019 Disease: Assessment on High-Resolution Computed Tomography Thorax.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives This particular study was undertaken to assess the role of high-resolution computed tomography (HRCT) thorax in diagnosing patients with novel Corona virus-2019 disease and screening suspected COVID-19 cases. It also involves an assessment of the severity of bilateral lung involvement in proven and suspected cases of COVID-19 infection. Materials and methods Two hundred and fourteen symptomatic cases referred to the department of radio-diagnosis were evaluated in this study. HRCT thorax was performed on SIEMENS Somatom Emotion 16-slice spiral CT. Initially, a tomogram was taken, followed by sections in the lung window at B90s, kVp 130, with a pitch of 1.15. The images are then reconstructed into 1.0-mm-thin slices. Radiologists then interpreted the scans for features of COVID-19 disease. Various imaging features and the severity of the disease were analysed in all patients. Results We observed that the male population was more affected by the disease (72% of the total cases). The most consistent and common HRCT finding is that of ground-glass opacity (GGO), which was present in 172 cases, corresponding to 78.4% of the cases. Crazy pavement appearance was seen in 41.2 % of the cases. Other findings included consolidation, discrete nodules surrounded by ground-glass opacification, subpleural linear opacities, and tubular bronchiectasis. Conclusion HRCT thorax plays an ideal role in diagnosing COVID-19 disease with high sensitivity and also provides prompt results as compared to RT-PCR. It also helps in grading the severity of the disease based on various patterns and the extent of lung parenchyma involved. Therefore, because of the immediate results and the ability to grade the disease, HRCT became invaluable in directing the treatment of COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.